Depreciation of ELITE PHARMACEUTICALS INC /NV/ from 31 Mar 2014 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly and annual Depreciation in USD history and change rate from 31 Mar 2014 to 31 Mar 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Depreciation for the quarter ending 31 Mar 2025 was $363,880, a 11% increase year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ Depreciation for the twelve months ending 31 Mar 2025 was $1,226,399, a 7.1% decline year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ annual Depreciation for 2024 was $1,226,399, a 7.1% decline from 2023.
  • ELITE PHARMACEUTICALS INC /NV/ annual Depreciation for 2023 was $1,320,518, a 6.7% increase from 2022.
  • ELITE PHARMACEUTICALS INC /NV/ annual Depreciation for 2022 was $1,237,770, a 3.6% increase from 2021.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $1,226,399 $363,880 +$35,498 +11% 01 Jan 2025 31 Mar 2025 10-K 30 Jun 2025 2025 FY
Q4 2024 $1,190,901 $313,060 -$23,554 -7% 01 Oct 2024 31 Dec 2024 10-Q 13 Feb 2025 2025 Q3
Q3 2024 $1,214,455 $227,356 -$99,884 -31% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024 2025 Q2
Q2 2024 $1,314,339 $322,103 -$6,179 -1.9% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024 2025 Q1
Q1 2024 $1,320,518 $328,382 +$13,977 +4.4% 01 Jan 2024 31 Mar 2024 10-K 30 Jun 2025 2025 FY
Q4 2023 $1,306,541 $336,614 +$22,004 +7% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025 2025 Q3
Q3 2023 $1,284,537 $327,240 +$11,233 +3.6% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2025 Q2
Q2 2023 $1,273,304 $328,282 +$35,534 +12% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2025 Q1
Q1 2023 $1,237,770 $314,405 +$17,128 +5.8% 01 Jan 2023 31 Mar 2023 10-K 01 Jul 2024 2024 FY
Q4 2022 $1,220,642 $314,610 +$21,596 +7.4% 01 Oct 2022 31 Dec 2022 10-Q 14 Feb 2024 2024 Q3
Q3 2022 $1,199,046 $316,007 +$20,516 +6.9% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2024 Q2
Q2 2022 $1,178,530 $292,748 -$16,409 -5.3% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2024 Q1
Q1 2022 $1,194,939 $297,277 +$82,785 +39% 01 Jan 2022 31 Mar 2022 10-K 29 Jun 2023 2023 FY
Q4 2021 $1,112,154 $293,014 -$212,973 -42% 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2023 2023 Q3
Q3 2021 $1,325,127 $295,491 +$40,373 +16% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2023 Q2
Q2 2021 $1,284,754 $309,157 -$14,914 -4.6% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2023 Q1
Q1 2021 $1,299,668 $214,492 -$108,668 -34% 01 Jan 2021 31 Mar 2021 10-K 29 Jun 2022 2022 FY
Q4 2020 $1,408,336 $505,987 +$179,079 +55% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022 2022 Q3
Q3 2020 $1,229,257 $255,118 -$73,022 -22% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2022 Q2
Q2 2020 $1,302,279 $324,071 -$3,337 -1% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2022 Q1
Q1 2020 $1,305,616 $323,160 +$11,601 +3.7% 01 Jan 2020 31 Mar 2020 10-K 14 Jun 2021 2021 FY
Q4 2019 $1,294,015 $326,908 +$9,290 +2.9% 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021 2021 Q3
Q3 2019 $1,284,725 $328,140 +$14,745 +4.7% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2021 Q2
Q2 2019 $1,269,980 $327,408 +$27,241 +9.1% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2021 Q1
Q1 2019 $1,242,739 $311,559 -$27,680 -8.2% 01 Jan 2019 31 Mar 2019 10-K 29 Jun 2020 2020 FY
Q4 2018 $1,270,419 $317,618 +$85,260 +37% 01 Oct 2018 31 Dec 2018 10-Q 10 Feb 2020 2020 Q3
Q3 2018 $1,185,159 $313,395 +$87,351 +39% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2020 Q2
Q2 2018 $1,097,808 $300,167 +$115,581 +63% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2020 Q1
Q1 2018 $982,227 $339,239 +$143,820 +74% 01 Jan 2018 31 Mar 2018 10-K 21 Jun 2019 2019 FY
Q4 2017 $838,407 $232,358 +$65,756 +39% 01 Oct 2017 31 Dec 2017 10-Q 11 Feb 2019 2019 Q3
Q3 2017 $772,651 $226,044 +$60,229 +36% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2019 Q2
Q2 2017 $712,422 $184,586 +$12,071 +7% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2019 Q1
Q1 2017 $700,351 $195,419 +$35,759 +22% 01 Jan 2017 31 Mar 2017 10-K 14 Jun 2018 2018 FY
Q4 2016 $664,592 $166,602 -$7,312 -4.2% 01 Oct 2016 31 Dec 2016 10-Q 09 Feb 2018 2018 Q3
Q3 2016 $671,904 $165,815 +$5,020 +3.1% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2018 Q2
Q2 2016 $666,884 $172,515 +$14,600 +9.2% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2018 Q1
Q1 2016 $652,284 $159,660 01 Jan 2016 31 Mar 2016 10-K 14 Jun 2018 2018 FY
Q4 2015 $173,914 01 Oct 2015 31 Dec 2015 10-Q 09 Feb 2017 2017 Q3
Q3 2015 $160,795 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2017 Q2
Q2 2015 $157,915 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2017 Q1

ELITE PHARMACEUTICALS INC /NV/ Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,226,399 -$94,119 -7.1% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025 2025 FY
2023 $1,320,518 +$82,748 +6.7% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025 2025 FY
2022 $1,237,770 +$42,831 +3.6% 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024 2024 FY
2021 $1,194,939 -$104,729 -8.1% 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023 2023 FY
2020 $1,299,668 -$5,948 -0.46% 01 Apr 2020 31 Mar 2021 10-K 29 Jun 2022 2022 FY
2019 $1,305,616 +$62,877 +5.1% 01 Apr 2019 31 Mar 2020 10-K 14 Jun 2021 2021 FY
2018 $1,242,739 +$260,512 +27% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2020 FY
2017 $982,227 +$281,876 +40% 01 Apr 2017 31 Mar 2018 10-K 21 Jun 2019 2019 FY
2016 $700,351 +$48,067 +7.4% 01 Apr 2016 31 Mar 2017 10-K 14 Jun 2018 2018 FY
2015 $652,284 +$86,256 +15% 01 Apr 2015 31 Mar 2016 10-K 14 Jun 2018 2018 FY
2014 $566,028 $0 0% 01 Apr 2014 31 Mar 2015 10-K 14 Jun 2017 2017 FY
2013 $566,028 01 Apr 2013 31 Mar 2014 10-K 15 Jun 2016 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.